文献-镇静剂||A型毒素的镇静剂效果

文献-镇痛||A型毒素在用作眉迷走神经节受阻治疗十分复杂地区性咳嗽病症

A型素在用作眉迷走神经节受阻治疗十分复杂地区性咳嗽病症：一项随机试验

Price背景：Price

本科学研究借此验证素在通过持续下降皮肤上气压延长眉迷走神经受阻持续时间的举例。译者透过了一项随机、CPA、相符合试验，科学研究a型素在治疗十分复杂地区性咳嗽病症高血压眉迷走神经节受阻的医学。

Price方法有：Price

换用75 IU A型素在（素在组）和全局止痛（小鼠），对下肢十分复杂地区性咳嗽病症高血压透过眉迷走神经节受阻。

主要结果是1个年末后受阻口足底与对口足底的比较温差转变。

次要结果是3个年末后的比较温差转变以及咳嗽强度转变。

Price结果：Price

仅有48名参与者（N=24/组）被随机分配。

素在组的比较气压增大高于小鼠（并列1.0±1.3℃ vs. 0.1±0.8℃；差异：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个年末，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与小鼠比起，素在组在1个年末（并列（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个年末（并列（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的咳嗽强度显著降低。

没有与素在针头相关的严重不良事件。

Price得出结论：Price

在十分复杂地区性咳嗽病症高血压之前，使用A型素在透过眉迷走神经节受阻可使患足气压下降3个年末，并再加咳嗽。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.